Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Phase 2 Completed 13 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupSingle-blindTreatment

Summary

This study will evaluate the efficacy of BGG492 in reducing the sensitivity to flashing lights of patients with photosensitive epilepsy, using EEG as a readout.

Timeline

Start: 2008-10
Primary completion: 2010-09
Completion: 2010-09

Publications

Kasteleijn-Nolst Trenite D, Brandt C, Mayer T, Rosenow F, Schmidt B, Steinhoff BJ, Gardin A, Imbert G, Johns D, Sagkriotis A, Kucher K. Dose-dependent suppression of human photoparoxysmal response with the competitive AMPA/kainate receptor antagonist BGG492: Clear PK/PD relationship. Epilepsia. 2015 Jun;56(6):924-32. doi: 10.1111/epi.13008. Epub 2015 May 11.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	selurampanel	Small molecule	15 mg	Oral
Subject	selurampanel	Small molecule	50 mg	Oral
Subject	selurampanel	Small molecule	100 mg	Oral

Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy

Summary

Timeline

Publications

Drugs

Indications